Thomas Folinsbee
Directeur/Membre du Conseil chez CASI PHARMACEUTICALS, INC.
Postes actifs de Thomas Folinsbee
Sociétés | Poste | Début | Fin |
---|---|---|---|
CASI PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 21/03/2023 | - |
Independent Dir/Board Member | 21/03/2023 | - | |
Shanghai Alebund Pharmaceuticals Ltd. | Corporate Officer/Principal | 01/01/2019 | - |
Historique de carrière de Thomas Folinsbee
Anciens postes connus de Thomas Folinsbee
Sociétés | Poste | Début | Fin |
---|---|---|---|
Bison Capital Acquisition Corp.
Bison Capital Acquisition Corp. Financial ConglomeratesFinance Bison Capital Acquisition Corp. is currently a blank check company, which primarily engages in the acquisition, and engagement in share exchange, share reconstruction and amalgamation with, contractual control arrangement with, purchasing all or substantially all of the assets of an entity. It also plans on engaging in any other similar business combination with one or more entities. The company is headquartered in Beijing, China. | Directeur/Membre du Conseil | 31/05/2017 | 01/01/2019 |
Independent Dir/Board Member | 31/05/2017 | 01/01/2019 | |
3SBIO INC. | Corporate Officer/Principal | 01/01/2009 | 01/01/2019 |
Hisanaga Seisakusho Co. Ltd. | Directeur/Membre du Conseil | 01/01/2011 | 01/01/2016 |
SUMT HEAL | Directeur/Membre du Conseil | - | - |
Independent Dir/Board Member | - | - | |
XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | Directeur/Membre du Conseil | 01/01/2019 | - |
Independent Dir/Board Member | 01/01/2019 | - |
Formation de Thomas Folinsbee
McGill University | Undergraduate Degree |
Statistiques
Internationale
Chine | 5 |
Îles Cayman | 3 |
Japon | 2 |
Opérationnelle
Director/Board Member | 5 |
Independent Dir/Board Member | 4 |
Corporate Officer/Principal | 2 |
Sectorielle
Health Technology | 4 |
Finance | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
3SBIO INC. | Health Technology |
CASI PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Bison Capital Acquisition Corp.
Bison Capital Acquisition Corp. Financial ConglomeratesFinance Bison Capital Acquisition Corp. is currently a blank check company, which primarily engages in the acquisition, and engagement in share exchange, share reconstruction and amalgamation with, contractual control arrangement with, purchasing all or substantially all of the assets of an entity. It also plans on engaging in any other similar business combination with one or more entities. The company is headquartered in Beijing, China. | Finance |
Xynomic Pharmaceuticals Holdings, Inc.
Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China. | Health Technology |
Hisanaga Seisakusho Co. Ltd. | |
Summit Healthcare Acquisition Corp.
Summit Healthcare Acquisition Corp. Financial ConglomeratesFinance Summit Healthcare Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The company was founded on December 22, 2020 and is headquartered in Hong Kong. | Finance |
Shanghai Alebund Pharmaceuticals Ltd. |
- Bourse
- Insiders
- Thomas Folinsbee
- Expérience